STOCK TITAN

Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Vyant Bio (Nasdaq: VYNT) is set to host an investor conference call and webcast on November 11, 2021, at 4:30 PM ET. The call will feature CEO Jay Roberts and CFO Andy LaFrence, who will discuss Q3 2021 corporate, scientific, financial, and operational results. Investors can participate through details available on the Vyant Bio website. The company focuses on developing therapeutics for central nervous system and oncology diseases, utilizing advanced technologies in drug discovery.

Positive
  • Vyant Bio focuses on drug discovery for CNS and oncology diseases.
  • Plans to file two investigational new drug applications annually.
Negative
  • None.

CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Thursday, November 11, 2021.

Jay Roberts, Chief Executive Officer, and Andy LaFrence, Chief Financial Officer, of Vyant Bio will highlight corporate, scientific, financial, and operational results achieved in the third quarter of 2021. Please also visit the Investors section of the Vyant Bio web site for details on how to participate.

Event:Investor Conference Call and Webcast for the Third Quarter 2021
Date:Thursday, November 11, 2021
Time:4:30 pm ET
Dial In:Toll Free: +1.877.545.0320 Conference ID: 478381
Webcast:https://www.webcaster4.com/Webcast/Page/2756/43513

The live event will be recorded and available for replay. The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com.

ABOUT VYANT BIO, INC.

Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering neurology and oncology drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia. The Company has five state-of-the-art labs and a scientific team with world experts in key areas who have been involved in over 200 investigational new drug applications and over 50 CNS and oncology studies and trials.

For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedInhttps://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

Investor Contact:
Jennifer K. Zimmons, PhD, MBA
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514

###


FAQ

When is Vyant Bio's investor conference call?

The investor conference call is scheduled for November 11, 2021, at 4:30 PM ET.

What will be discussed during the Vyant Bio conference call?

The conference call will cover Q3 2021 corporate, scientific, financial, and operational results.

How can I join the Vyant Bio investor conference call?

Participation details for the conference call are available on Vyant Bio's website.

What is Vyant Bio's focus in drug discovery?

Vyant Bio focuses on developing therapeutics for central nervous system and oncology-related diseases.

What is the ticker symbol for Vyant Bio?

Vyant Bio's ticker symbol is VYNT.

Vyant Bio, Inc.

OTC:VYNT

VYNT Rankings

VYNT Latest News

VYNT Stock Data

1.23M
5.10M
18.78%
0.64%
3.27%
Biotechnology
Healthcare
Link
United States
Cherry Hill